Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

As the need to draw awareness to cervical, ovarian, uterine/endometrial, vaginal, and vulvar cancer becomes more evident, ...

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

HAMPTON TOWNSHIP, Pa. (KDKA) -- The National Ovarian Cancer Coalition Great Lakes chapter held its biggest fundraiser of the ...

From model Bianca Balti’s ovarian cancer diagnosis to hockey pro’s testicular cancer diagnosis, here’s what’s happening in ...

Dr. Diego Aviles with UT Physicians says symptoms of ovarian cancer typically include bloating, pain in the stomach or pelvis ...

September is recognized as Ovarian Cancer Awareness Month. But, do you know the signs and symptoms that could be impacting ...

Ovarian cancer is a type of cancer that impacts the female reproductive system. The risk of developing ovarian cancer in a woman's lifetime is 1 in 87, according to the American Cancer Society (ACS).

Researchers investigated RA51C and uncovered over 3,000 harmful genetic changes that could increase cancer risk.

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

New research identifies specific genetic changes that can increase a person's risk of breast and ovarian cancers, to help guide clinical decision-making.